From the results it was evident that this modification in PCR using PNA was an accurate and sensitive method to screen pancreatic cancer patients with KRAS mutation, apart from screening, this method also has potential to quantify KRAS mutant DNA to envisage response of cancer patients towards therapy and monitoring of disease progression. Here, KRAS is linked to familial pancreatic carcinoma.